If your biotech company needs to move from lab-scale cell culture to pilot or pre-commercial production, Canada’s NRC Cell Culture Pilot Plant can be a key resource. Many small biotech companies do not have the right facilities, staff, or money to make products safely. The National Research Council of Canada (NRC) operates this federal facility to help companies test and improve their products before selling them.
The NRC — Cell Culture Pilot Plant is a fee-for-service biomanufacturing facility operated by the National Research Council of Canada. It supports process development and scale-up using animal cell culture systems.
Key points to understand up front:
This makes the NRC Cell Culture Pilot Plant especially relevant if you are preparing for regulatory submissions, moving your process to another manufacturer, or preparing for investors.
The NRC Cell Culture Pilot Plant supports biologics and vaccine development using established mammalian expression systems.
Projects are scoped collaboratively with NRC scientists to ensure technical fit and realistic timelines.
There is no formal published eligibility checklist, but the facility is intended for organizations with a clear R&D or commercialization objective.
You are a strong fit if you are:
Because this is a paid service, the NRC focuses on technical feasibility and alignment with its mandate, rather than company size or revenue.
Access follows a structured but practical process:
Because capacity is limited, early outreach matters—especially if your timelines are tied to clinical or investor milestones.
Tools like GrantHub’s eligibility matcher can help you filter complementary programs by province and industry in seconds, including grants that may offset related R&D costs.
While the NRC Cell Culture Pilot Plant itself is not a grant, it often works alongside funding programs.
Important considerations:
GrantHub tracks active federal and provincial programs that may match your biomanufacturing plans.
The NRC Cell Culture Pilot Plant is strictly fee-for-service. Budgeting incorrectly can delay approvals.
Pilot plant capacity is limited. Waiting until you need material urgently can put your timelines at risk.
Vague objectives lead to longer scoping phases and higher costs. Be clear about scale, timelines, and end use.
Pilot-scale success should align with eventual transfer to another manufacturer or your own GMP facility.
Q: Is the NRC Cell Culture Pilot Plant a grant program?
No. It is a paid service offered by the National Research Council of Canada. You contract directly with the NRC for defined technical work.
Q: What types of products are suitable for this facility?
The pilot plant supports biologics and vaccines produced using mammalian cell culture, including CHO and HEK 293 systems.
Q: Do I need to be a Canadian company to use it?
There is no strict public eligibility rule. Canadian companies and those collaborating with Canadian partners are the most common users.
Q: Can NRC pilot plant costs be claimed under SR&ED?
In some cases, yes. Eligibility depends on whether the work meets SR&ED criteria and how the contract is structured. Always confirm with a qualified advisor.
Q: How long does it take to start a project?
Timelines vary. Initial scoping can take weeks, followed by scheduling based on facility availability and project complexity.
If you are planning biologics scale-up in Canada, the NRC Cell Culture Pilot Plant can be a strategic bridge between lab research and commercial manufacturing. Pairing this service with the right grants and tax credits can significantly reduce your cash burn.
GrantHub tracks active grant programs across Canada—check which ones match your biomanufacturing stage, province, and technology focus.
See also:
Was this article helpful?
Rate it so we can improve our content.
Canada Proactive Disclosure Data
The Canadian government has funded over 400,000 businesses through 1.27 million grants and contributions. Check your eligibility in 60 seconds.